DAFNA Capital Management’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

DAFNA Capital Management’s Portfolio TBRA Stock Details TBRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-81,402	Closed	-$666K	–	108
2016 Q1	$666K	Sell	81,402 -78,951	-49%	-$596K	0.57%	49
2015 Q4	$1.61M	Buy	160,353 +115,261	+256%	+$1.2M	1.44%	23
2015 Q3	$436K	Buy	+45,092	New	+$633K	0.43%	60
2014 Q3	–	Sell	-3,333	Closed	-$204K	–	64
2014 Q2	$204K	Buy	+3,333	New	+$203K	0.19%	45

Other funds holding TBRA

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

DAFNA Capital Management's TBRA Position: Q2 2016 in Review

DAFNA Capital Management sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q2 2016, closing a stake of 81,402 shares — an estimated $666K sold.

DAFNA Capital Management first reported a position in TBRA in Q2 2014 and held it in 4 quarters. The position peaked at $1.61M in Q4 2015. 45 funds tracked by Wall St. Rank hold TBRA as of Q2 2016.

DAFNA Capital Management reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
DAFNA Capital Management sold 81,402 Tobira Therapeutics, Inc. Common Stock shares in Q2 2016, an estimated $666K.
DAFNA Capital Management first reported a position in Tobira Therapeutics, Inc. Common Stock in Q2 2014 and held it in 4 quarters.
DAFNA Capital Management's Tobira Therapeutics, Inc. Common Stock position peaked at $1.61M in Q4 2015.
45 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q2 2016.

Based on DAFNA Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.